04 April 2024
On 4 April 2024, the Management Committee of Guangzhou Development Zone and the People’s Government of Huangpu District issued the “Measures for Promoting the High-Quality Development of the Biopharmaceutical Industry in Guangzhou Development Zone (Huangpu District)” (“the Measures”). The Measures proposed to encourage medical institutions to enhance their capabilities in conducting clinical trials for new drugs. For clinical trial institutions that comply with the Good Clinical Practice (“GCP”) standards for drug clinical trials, a subsidy of RMB 300,000 will be provided for each additional GCP professional discipline, with a maximum annual subsidy of RMB 1.5 million each institution. This Measures will be implemented from 4 April 2024 and will be valid for 3 years.